Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.

医学 吉西他滨 内科学 肿瘤科 紫杉醇 化疗 胆囊癌 顺铂 紫杉醇 癌症 毒性 胃肠病学 养生 不利影响
作者
Ting Liu,Qing Li,Wenjie Zhang,Qing Zhu
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:11: 733955-
标识
DOI:10.3389/fonc.2021.733955
摘要

Background Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcitabine, cisplatin, plus nab-paclitaxel is currently considered an effective option for patients with advanced BTC following the results of a phase II trial. In addition, maintenance therapy after first-line treatment has been shown to improve disease control rate of various solid tumors but has not been evaluated for GBC patients. The scenario we report herein is of a metastatic GBC patient treated with the triple-drug regimen followed by maintenance therapy with capecitabine or S-1, who achieved a long-term survival benefit. Case Presentation A 68-year-old man was diagnosed with gallbladder adenocarcinoma with liver, supra-diaphragmatic, and abdominal lymph node metastases (cT3N2M1, stage IVB). Partial response (PR) was achieved after five cycles of gemcitabine and cisplatin chemotherapy. A further three cycles of nab-paclitaxel plus gemcitabine-cisplatin regimen yielded a complete response of all tumor lesions. Subsequent administration of maintenance therapy with capecitabine followed by S-1 achieved a disease-free survival of 15 months for the patient. Moreover, the patient remained responsive to this triple-drug regimen when the disease progressed, achieving PR after two cycles of chemotherapy. Overall, the treatment regimens were well tolerated with no grade 3 or higher adverse effects occurring. Notably, the serum carbohydrate antigen 199 (CA199) levels were closely related to the treatment response and increased before the lesions were found on PET-CT during follow-up. Conclusion Our findings suggested that adding nab-paclitaxel into gemcitabine-cisplatin regimen may result in a favorable efficacy in patients with advanced GBC. Further maintenance therapy with capecitabine or S-1 after first-line therapy appeared to be a reasonable option for these patients, and it is valuable to monitor CA199 levels during treatment and follow-up.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
斯文败类的应助被英勇的铸海采纳,获得10
刚刚
华仔的应助被liu采纳,获得10
刚刚
1秒前
liuze发布了新的文献求助10
1秒前
哈弟发布了新的文献求助10
1秒前
搜集达人的应助被害羞的宛亦采纳,获得10
2秒前
hin完成签到,获得积分20
2秒前
2秒前
三达不溜发布了新的文献求助10
2秒前
3秒前
赘婿的应助被maT采纳,获得10
3秒前
慕青的应助被紧张的文博采纳,获得10
3秒前
HANA发布了新的文献求助10
4秒前
rrr关闭了rrr的文献求助
4秒前
小蘑菇的应助被直率万声采纳,获得10
5秒前
烦烦烦发布了新的文献求助10
5秒前
LuoYR@SZU发布了新的文献求助10
6秒前
6秒前
隐形曼青的应助被晚风采纳,获得10
6秒前
wangbw发布了新的文献求助10
7秒前
聪明甜桃发布了新的文献求助10
8秒前
默默发布了新的文献求助10
9秒前
10秒前
笙笙的应助被tomatoGG采纳,获得10
10秒前
11秒前
13秒前
lby关注了科研通微信公众号
13秒前
灿烂sunfly发布了新的文献求助10
13秒前
13秒前
风姿物语完成签到,获得积分10
14秒前
田様的应助被NAN采纳,获得10
15秒前
15秒前
16秒前
忧郁的莫茗完成签到,获得积分10
17秒前
小橘完成签到,获得积分10
19秒前
李爱国的应助被科研不是科幻采纳,获得10
19秒前
19秒前
20秒前
enkidu发布了新的文献求助10
20秒前
也未可知完成签到 ,获得积分0
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593